“We hope to be in human [trials] within a year,” said Sanofi’s head of global vaccine research and development John Shiver.
These partnerships aim to get Covid-19 vaccine candidates “into clinical testing as quickly as possible,” GSK said in a statement.
But “by then, interest in a coronavirus vaccine was basically gone,” Baylor’s Peter Hotez explained.
While there’s now a push to understand the immune enhancement phenomenon, it might pose a problem for new Covid-19 vaccines.
As with vaccines, scientists are investigating dozens of drugs to treat Covid-19, building on past work treating other viruses and diseases, from SARS to HIV.